Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients

World Journal of Gastroenterology

Volumn 18, Issue 32, 2012, Pages 4391-4398

  Aguas, Mariam ^a   Bastida, Guillermo ^a   Cerrillo, Elena ^a   Beltrán, Belén ^a   Iborra, Marisa ^a   Sánchez Montes, Cristina ^a   Muñoz, Fernando ^b   Barrio, Jesús ^c   Riestra, Sabino ^d   Nos, Pilar ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Leon Hospital Complex   (Spain)

^c HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^d Central University Hospital of Asturias   (Spain)

Author keywords

Adalimumab; Crohn's disease; Postoperative recurrence; Prevention; Tumor necrosis factor alpha agents

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; IMMUNOMODULATING AGENT; INFLIXIMAB;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CROHN DISEASE; DRUG EFFICACY; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RECURRENT DISEASE; SCORING SYSTEM; SMOKING; VERTIGO;

EID: 84867717551     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i32.4391     Document Type: Article

References (32)

1. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60
2. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OØ, Munkholm P. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481-489
3. Nos P, Domenech E. Postoperative Crohn's disease recurrence: a practical approach. World J Gastroenterol 2008; 14: 5540-5548
4. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn' s disease. Gastroenterology 1990; 99: 956-963
5. Sailer J, Peloschek P, Reinisch W, Vogelsang H, Turetschek K, Schima W. Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol 2008; 18: 2512-2521
6. Koilakou S, Sailer J, Peloschek P, Ferlitsch A, Vogelsang H, Miehsler W, Fletcher J, Turetschek K, Schima W, Reinisch W. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis 2010; 16: 198-203
7. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127: 730-740
8. D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135: 1123-1129
9. Domènech E, Mañosa M, Bernal I, Garcia-Planella E, Cabré E, Piñol M, Lorenzo-Zúñiga V, Boix J, Gassull MA. Impact of azathioprine on the prevention of postoperative Crohn' s disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis 2008; 14: 508-513
10. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-729
11. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621
12. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861
13. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 2012; 35: 625-633
14. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-450. e1; quiz 716
15. Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 167: 1804-1807
16. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
17. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591
18. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010; 24 Suppl 1: 3-14
19. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838
20. Leyendecker JR, Bloomfeld RS, DiSantis DJ, Waters GS, Mott R, Bechtold RE. MR enterography in the management of patients with Crohn disease. Radiographics 2009; 29: 1827-1846
21. Seigel DG, Podgor MJ, Remaley NA. Acceptable values of kappa for comparison of two groups. Am J Epidemiol 1992; 135: 571-578
22. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; (4): CD006873
23. Yamamoto T. Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. World J Gastroenterol 2010; 16: 5405-5410
24. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009; 15: 1460-1466
25. Savarino E, Dulbecco P, Bodini G, Assandri L, Savarino V. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. Eur J Gastroenterol Hepatol 2012; 24: 468-470
26. Ahmed T, Rieder F, Fiocchi C, Achkar JP. Pathogenesis of postoperative recurrence in Crohn's disease. Gut 2011; 60: 553-562
27. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn' s disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213-1221
28. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-1099
29. Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn' s disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187: 219-225
30. Regueiro M, Kip KE, Schraut W, Baidoo L, Sepulveda AR, Pesci M, El-Hachem S, Harrison J, Binion D. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17: 118-126
31. Walters TD, Steinhart AH, Bernstein CN, Tremaine W, McKenzie M, Wolff BG, McLeod RS. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 2011; 17: 1547-1556
32. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61: 229-234